• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by IGC Pharma Inc.

    8/18/25 6:56:14 PM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IGC alert in real time by email
    DEFA14A 1 igcdefa14a081825.htm FORM DEFA14A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 14A

     

     

     

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

     

    Filed by the Registrant ☒

     

    Filed by a Party other than the Registrant ☐

     

    Check the appropriate box:

     

    ☐ Preliminary Proxy Statement
       
    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
       
    ☐ Definitive Proxy Statement
       
    ☒ Definitive Additional Materials
       
    ☐ Soliciting Material Pursuant to §240.14a-12

     

    igcpharma20240709_defa14aimg001.jpg

    IGC Pharma, Inc.

    (Exact name of registrant as specified in its charter)

     

                                                                                                            

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒ No fee required.
       
    ☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
       
    ☐ Fee paid previously with preliminary materials.
       
    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

     

      Your Vote Counts!
    IGC PHARMA, INC.
    2025 Annual Meeting
    Vote by October 09, 2025
    11:59 PM ET
       
     

     

    You invested in IGC PHARMA, INC. and it's time to vote!

     

    You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the shareholder meeting to be held on October 10, 2025.

     

    Get informed before you vote

     

    View the Notice & Proxy Statement, Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to September 28, 2025. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

     

     

     

     

        Vote in Person at the Meeting*
    October 10, 2025
    11:00 AM EST
           
        10224 Falls Road
    Potomac, Maryland, 20854

     

    *If you choose to vote these shares in person at the meeting, you must request a “legal proxy.” To do so, please follow the instructions at www.ProxyVote.com or request a paper copy of the materials, which will contain the appropriate instructions. Please check the meeting materials for any special requirements for meeting attendance.

     

     

    THIS IS NOT A VOTABLE BALLOT

    This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters.

    IGC PHARMA, INC.

    2025 Annual Meeting

    Vote by October 09, 2025

    11:59 PM ET

     

    Voting Items Board
    Recommends
           
    1. Election of Directors  For
      Nominees:  
    1A MR. RAM MUKUNDA    
    1B MR. JAMES MORAN  For
    2 To ratify the appointment of Manohar Chowdhry & Associates, as the Company’s independent registered public accounting firm for the 2026 fiscal year  For
    3 To approve the grant of 5,000,000 shares of common stock, governed by the Company’s 2018 Omnibus Incentive Plan, to be granted from time to time to the Company’s current and new employees, advisors, directors, and consultants by the Board of Directors, pursuant to certain metrics including performance, vesting, and incentive as set by the Board of Directors and or the CEO  For
    4 To effect an amendment to our Amended and Restated Articles of Incorporation to increase the authorized number of shares of our common stock from 150,000,000 shares to 600,000,000 shares of common stock  For
    5 To act upon such other matters as may properly come before the Annual Meeting, including any proposal to adjourn or postpone of the Annual Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies (the Adjournment Proposal) Such other business as may properly come before the meeting or any adjournment thereof  For

     

    Get the next $IGC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IGC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IGC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IGC Pharma Appoints Former Virginia Governor Terry McAuliffe as Strategic Advisor

    POTOMAC, MD / ACCESS Newswire / January 21, 2025 / IGC Pharma, Inc. (NYSE:IGC) ("IGC Pharma" or the "Company") is pleased to announce the appointment of Terry McAuliffe, the 72nd Governor of Virginia, as a strategic advisor. Governor McAuliffe's extensive leadership experience across public and private sectors will play a pivotal role in advancing IGC Pharma's mission to redefine Alzheimer's care and position the Company for growth in the biotechnology and pharmaceutical industries. As strategic advisor, Governor McAuliffe will focus on refining IGC Pharma's growth strategies, driving business development initiatives, and fostering partnerships with leading pharmaceutical and healthcare o

    1/21/25 8:30:00 AM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets

    POTOMAC, MD / ACCESSWIRE / January 13, 2025 / IGC Pharma, Inc (NYSE:IGC) ("IGC" or the "Company"), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi will be participating in a fireside chat hosted by Ascendiant Capital Markets on Thursday, January 23, 2025, at 1:00 pm ET. During the session, IGC Pharma's management will provide insights into the Company's recent progress, including advancements in its Alzheimer's pipeline, strategic expansion into metabolic disorders, and the integration of artificial intelligence in drug discovery. They will also discuss key upcoming milestones, including new clinical trial launches, preclinical developments, and efforts to broaden the Compa

    1/13/25 8:30:00 AM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy

    Innovative use of geofencing technology boosts enrollment at select sites POTOMAC, MD / ACCESSWIRE / January 8, 2025 / IGC Pharma, Inc. (NYSE:IGC) ("IGC Pharma" or the "Company") announced today that its ongoing Phase 2 trial for agitation in Alzheimer's disease has been officially named CALMA (Calming Agitation in Alzheimer's).The trial's new identity reflects its mission to address agitation, a syndrome affecting up to 76% of the 55 million Alzheimer's patients worldwide that also adversely impacts the quality of life for both patients and their caregivers.To accelerate enrollment across all clinical sites, IGC Pharma has implemented an innovative recruitment campaign leveraging geofencing

    1/8/25 8:30:00 AM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IGC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Prins Richard K converted options into 228,333 shares, increasing direct ownership by 22% to 1,271,251 units (SEC Form 5)

    5 - IGC Pharma, Inc. (0001326205) (Issuer)

    5/15/25 4:11:18 PM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mukunda Ram converted options into 566,666 shares, increasing direct ownership by 16% to 4,092,678 units (SEC Form 5)

    5 - IGC Pharma, Inc. (0001326205) (Issuer)

    5/15/25 4:10:28 PM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Moran James P converted options into 163,333 shares, increasing direct ownership by 17% to 1,105,735 units (SEC Form 5)

    5 - IGC Pharma, Inc. (0001326205) (Issuer)

    5/15/25 4:09:37 PM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IGC
    SEC Filings

    View All

    IGC Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - IGC Pharma, Inc. (0001326205) (Filer)

    10/1/25 4:40:35 PM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by IGC Pharma Inc.

    424B5 - IGC Pharma, Inc. (0001326205) (Filer)

    9/19/25 4:02:45 PM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by IGC Pharma Inc.

    DEFA14A - IGC Pharma, Inc. (0001326205) (Filer)

    8/18/25 6:56:14 PM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IGC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Moran James P bought $200,000 worth of shares (588,235 units at $0.34) (SEC Form 4)

    4 - IGC Pharma, Inc. (0001326205) (Issuer)

    9/27/24 4:05:18 PM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IGC
    Financials

    Live finance-specific insights

    View All

    IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer's Pipeline

    POTOMAC, MD / ACCESSWIRE / November 14, 2024 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE:IGC) today announced its financial results and strategic advancements for the second fiscal quarter of 2025 ended September30, 2024. The quarter was marked by significant progress in the Company's pipeline, particularly in the development of potential treatments for Alzheimer's and other neurological and metabolic disorders. IGC Pharma, Inc. Q2 FY2025 Company's HighlightsCrossing the Blood-Brain Barrier with TGR-63: July 9, 2024 - Preclinical analyses for TGR-63 demonstrated this compound's ability to cross the blood-brain barrier with a favorable safety profile, positioning it for further therap

    11/14/24 8:30:00 AM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IGC Pharma Reports First Quarter Fiscal 2025 Results

    IGC Pharma, Inc. ("IGC" or the "Company") (NYSE:IGC) today announced its financial results for the first fiscal quarter of 2025 ended June 30, 2024. Q1 FY2025 Company's Highlights On April 9, 2024, the Company welcomed Pablo Arbelaez, Ph.D., a renowned AI expert and researcher, to support the development of the Phase 2 clinical trial of IGC-AD1, the lead therapeutic candidate addressing agitation in Alzheimer's disease. On April 16, 2024, the Company announced that interim data from its Phase 2 clinical trial demonstrates a clinically significant reduction, approaching statistical significance, in agitation in Alzheimer's at week two compared to placebo. On May 28, 2024, the Comp

    8/8/24 9:30:00 PM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IGC Reports Financial Results for Fiscal Year Ended March 31, 2024

    IGC Pharma, Inc. ("IGC" or the "Company") (NYSE:IGC), a clinical-stage pharmaceutical company, has announced its financial results for the fiscal year ended March 31, 2024 ("Fiscal 2024"). Full Fiscal Year Highlights In March 2024, the Company announced positive interim results from its ongoing Phase 2 trial for IGC-AD1. The interim data have shown promising results in reducing Alzheimer's agitation, which is a major challenge for patients and their caregivers alike. This development marks a significant step forward in the fight against Alzheimer's and brings hope to millions of people affected by this devastating disease. In January 2024, the Company announced details about its dru

    6/24/24 7:30:00 PM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IGC
    Leadership Updates

    Live Leadership Updates

    View All

    IGC Pharma Appoints Former Virginia Governor Terry McAuliffe as Strategic Advisor

    POTOMAC, MD / ACCESS Newswire / January 21, 2025 / IGC Pharma, Inc. (NYSE:IGC) ("IGC Pharma" or the "Company") is pleased to announce the appointment of Terry McAuliffe, the 72nd Governor of Virginia, as a strategic advisor. Governor McAuliffe's extensive leadership experience across public and private sectors will play a pivotal role in advancing IGC Pharma's mission to redefine Alzheimer's care and position the Company for growth in the biotechnology and pharmaceutical industries. As strategic advisor, Governor McAuliffe will focus on refining IGC Pharma's growth strategies, driving business development initiatives, and fostering partnerships with leading pharmaceutical and healthcare o

    1/21/25 8:30:00 AM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IGC Announces Results of its 2024 Annual Stockholders Meeting

    IGC Pharma, Inc. ("IGC" or the "Company") (NYSE:IGC) announces that during its Annual Meeting of Stockholders scheduled for and convened on August 23, 2023 (the "Annual Meeting"), all proposals as disclosed on the Definitive Proxy Statement on Schedule 14A filed with the SEC on July 8, 2024, were passed by the requisite vote of the stockholders. Only stockholders of record on the record date of June 28, 2024, were entitled to and requested to vote at the Annual Meeting. At the Annual Meeting, all of the following proposals were approved by the requisite vote of the stockholders: (i) the election of Mr. Richard Prins and Mr. Terry Lierman to the Company's board of directors to serve as Cla

    8/26/24 7:00:00 PM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer's Pipeline

    IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE:IGC) today announced that it has appointed Terry Lierman as an independent director to its board of directors. Mr. Lierman is currently Co-Chair of the Board of Advisors at the Institute of Human Virology (IHV), a center in the U.S. focused on accelerating the discovery of diagnostics and therapeutics for deadly viral and immune disorders and a member of the Board of Visitors at the La Follette School of Public Affairs at the University of Wisconsin, his alma mater. Terry founded the Children's Research Institute, one of America's top children's research programs, the Pancreatic Cancer Action Network (PanCAN), and the National

    3/12/24 3:00:00 PM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IGC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by IGC Pharma Inc.

    SC 13D/A - IGC Pharma, Inc. (0001326205) (Subject)

    8/14/24 4:23:18 PM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by IGC Pharma Inc.

    SC 13D - IGC Pharma, Inc. (0001326205) (Subject)

    5/21/24 9:20:27 PM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care